CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 460-467

  Liu, Shuwen ^a   Li, Runming ^a   Zhang, Ruitao ^a   Chan, Chris C S ^b   Xi, Baomin ^a   Zhu, Zhibo ^a   Yang, Jie ^a   Poon, Vincent K M ^b   Zhou, Jie ^b   Chen, Min ^b   Münch, Jan ^c   Kirchhoff, Frank ^c   Pleschka, Stephan ^d   Haarmann, Thomas ^e   Dietrich, Ursula ^e   Pan, Chungen ^f   Du, Lanying ^f   Jiang, Shibo ^a,f   Zheng, Bojian ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^f NEW YORK BLOOD CENTER   (United States)

Author keywords

CL 385319; H5N1 influenza A virus; HA2; Hemagglutinin; Virus entry inhibitor

Indexed keywords

ANTIVIRUS AGENT; CL 385319; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ADSORPTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PSEUDOTYPING; VIRUS ENTRY; VIRUS PARTICLE; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; DOGS; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; HYDROCARBONS, FLUORINATED; INFLUENZA A VIRUS, H5N1 SUBTYPE; MODELS, MOLECULAR; PIPERIDINES; PROTEIN CONFORMATION; VIRUS INTERNALIZATION;

EID: 79956103650     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.013     Document Type: Article

References (30)

1. Chen, H., Smith, G.J., Li, K.S., Wang, J., Fan, X.H., Rayner, J.M., Vijaykrishna, D., Zhang, J.X., Zhang, L.J., Guo, C.T., Cheung, C.L., Xu, K.M., Duan, L., Huang, K., Qin, K., Leung, Y.H., Wu, W.L., Lu, H.R., Chen, Y., Xia, N.S., Naipospos, T.S., Yuen, K.Y., Hassan, S.S., Bahri, S., Nguyen, T.D., Webster, R.G., Peiris, J.S., Guan, Y., 2006. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl. Acad. Sci. U. S. A. 103, 2845-2850.
2. Chou, T.C., Talalay, P., 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul. 22, 27-55.
3. Cianci, C., Yu, K.L., Dischino, D.D., Harte, W., Deshpande, M., Luo, G., Colonno, R.J., Meanwell, N.A., Krystal, M., 1999. pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion. J. Virol. 73, 1785-1794. (Pubitemid 29098077)
4. Dawood, F.S., Jain, S., Finelli, L., Shaw, M.W., Lindstrom, S., Garten, R.J., Gubareva, L.V., Xu, X., Bridges, C.B., Uyeki, T.M., 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360, 2605-2615.
5. Doucette, K.E., Aoki, F.Y., 2001. Oseltamivir: a clinical and pharmacological perspective. Expert. Opin. Pharmacother. 2, 1671-1683.
6. Du, L., Zhao, G., Zhang, X., Liu, Z., Yu, H., Zheng, B.J., Zhou, Y., Jiang, S., 2010. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem. Biophys. Res. Commun. 397, 580-585.
7. Gilbert, M., Xiao, X., Pfeiffer, D.U., Epprecht, M., Boles, S., Czarnecki, C., Chaitaweesub, P., Kalpravidh, W., Minh, P.Q., Otte, M.J., Martin, V., Slingenbergh, J., 2008. Mapping H5N1 highly pathogenic avian influenza risk in Southeast Asia. Proc. Natl. Acad. Sci. U. S. A. 105, 4769-4774.
8. Gupta, R.K., Nguyen-Van-Tam, J.S., 2006. Oseltamivir resistance in influenza A (H5N1) infection. N. Engl. J. Med. 354, 1423-1424.
9. Harrison, S.C., 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690-698.
10. He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., Jiang, S., 2004. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324, 773-781.
11. Hsieh, H.P., Hsu, J.T., 2007. Strategies of development of antiviral agents directed against influenza virus replication. Curr. Pharm. Des. 13, 3531-3542.
12. Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., Debnath, A.K., 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents. Chemother. 48, 4349-4359.
13. Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen, K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y., Kawaoka, Y., 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108. (Pubitemid 41509341)
14. Liu, S., Xiao, G., Chen, Y., He, Y.X., Niu, J.K., Escalante, C.R., Xiong, H.B., Farmar, J., Debnath, A.K., Tien, P., Jiang, S.B., 2004. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938-947. (Pubitemid 38388327)
15. Luo, G., Torri, A., Harte, W.E., Danetz, S., Cianci, C., Tiley, L., Day, S., Mullaney, D., Yu, K.L., Ouellet, C., Dextraze, P., Meanwell, N., Colonno, R., Krystal, M., 1997. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J. Virol. 71, 4062-4070. (Pubitemid 27172422)
16. MacArthur, R.D., Novak, R.M., 2008. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47, 236-241.
17. Moscona, A., 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360, 953-956.
18. Oldfield, V., Keating, G.M., Plosker, G., 2005. Enfuvirtide: a review of its use in the management of HIV infection. Drugs 65, 1139-1160. (Pubitemid 40846445)
19. Plotch, S.J., O'Hara, B., Morin, J., Palant, O., LaRocque, J., Bloom, J.D., Lang Jr., S.A., DiGrandi, M.J., Bradley, M., Nilakantan, R., Gluzman, Y., 1999. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J. Virol. 73, 140-151. (Pubitemid 28565355)
20. Reed, M.L., Yen, H.L., DuBois, R.M., Bridges, O.A., Salomon, R., Webster, R.G., Russell, C.J., 2009. Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein. J. Virol. 83, 3568-3580.
21. Reed, M.L., Bridges, O.A., Seiler, P., Kim, J.K., Yen, H.L., Salomon, R., Govorkova, E.A., Webster, R.G., Russell, C.J., 2010. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J. Virol. 84, 1527-1535.
22. Russell, R.J., Kerry, P.S., Stevens, D.J., Steinhauer, D.A., Martin, S.R., Gamblin, S.J., Skehel, J.J., 2008. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. U. S. A. 105, 17736-17741.
23. Skehel, J., 2009. An overview of influenza haemagglutinin and neuraminidase. Biologicals 37, 177-178.
24. Skehel, J.J., Wiley, D.C., 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569.
25. Sui, H.Y., Zhao, G.Y., Huang, J.D., Jin, D.Y., Yuen, K.Y., Zheng, B.J., 2009. Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. PLoS. One. 4, e5671.
26. Thoennes, S., Li, Z.N., Lee, B.J., Langley, W.A., Skehel, J.J., Russell, R.J., Steinhauer, D.A., 2008. Analysis of residues near the fusion peptide in the influenza hemagglutinin structure for roles in triggering membrane fusion. Virology 370, 403-414. (Pubitemid 350199676)
27. Wang, M., Di, B., Zhou, D.H., Zheng, B.J., Jing, H., Lin, Y.P., Liu, Y.F., Wu, X.W., Qin, P.Z., Wang, Y.L., Jian, L.Y., Li, X.Z., Xu, J.X., Lu, E.J., Li, T.G., Xu, J., 2006. Food markets with live birds as source of avian influenza. Emerg. Infect. Dis. 12, 1773-1775.
28. Yamada, S., Suzuki, Y., Suzuki, T., Le, M.Q., Nidom, C.A., Sakai-Tagawa, Y., Muramoto, Y., Ito, M., Kiso, M., Horimoto, T., Shinya, K., Sawada, T., Kiso, M., Usui, T., Murata, T., Lin, Y., Hay, A., Haire, L.F., Stevens, D.J., Russell, R.J., Gamblin, S.J., Skehel, J.J., Kawaoka, Y., 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444, 378-382. (Pubitemid 44764114)
29. Yoshimoto, J., Kakui, M., Iwasaki, H., Sugimoto, H., Fujiwara, T., Hattori, N., 2000. Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor. Stachyflin. Microbiol. Immunol. 44, 677-685.
30. Zheng, B., Mittal, S.K., Graham, F.L., Prevec, L., 1994. The E1 sequence of bovine adenovirus type 3 and complementation of human adenovirus type 5 E1A function in bovine cells. Virus. Res. 31, 163-186.